Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 28, 2021

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2027

Conditions

Gastric Cancer by AJCC V8 StageResectable Carcinoma

Interventions

DRUG

perioperative treatment

FLOT + Spartalizumab

Trial Locations (13)

CHU Besançon, Besançon

Centre François Baclesse, Caen

Centre Georges Francois Leclerc, Dijon

Chru Lille, Lille

APHM Marseille, Marseille

Institut Régional Cancer, Montpellier

APHP St Louis, Paris

Institut Mutualiste Montsouris, Paris

CHU Poitiers, Poitiers

CHU Robert Debré, Reims

Centre Eugène Marquis, Rennes

ICO St Herblain, Saint-Herblain

CH St Malo, St-Malo

All Listed Sponsors

collaborator

National Cancer Institute, France

OTHER_GOV

lead

Centre Francois Baclesse

OTHER